Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc., a leading biopharmaceutical company based in the United States, focuses on developing innovative treatments for neuropsychiatric diseases. Founded in 2002, the company has made significant strides in the industry, particularly with its flagship product, Caplyta (lumateperone), which has garnered attention for its unique mechanism of action in treating schizophrenia and bipolar depression. With a strong presence in the US and expanding operations in key global markets, Intra-Cellular Therapies is committed to addressing unmet medical needs through its cutting-edge research and development efforts. The company’s dedication to advancing mental health therapies positions it as a notable player in the biopharmaceutical landscape, with a focus on improving patient outcomes and enhancing quality of life.
DitchCarbon Score
How does Intra-Cellular Therapies, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Intra-Cellular Therapies, Inc.'s score of 46 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Intra-Cellular Therapies, Inc.'s reported carbon emissions
Intra-Cellular Therapies, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without reported emissions figures, it is challenging to assess their carbon footprint or climate commitments accurately. The absence of documented reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As the pharmaceutical industry increasingly prioritises sustainability, Intra-Cellular Therapies may need to establish clear climate goals and reporting practices to align with industry standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Intra-Cellular Therapies, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
